| Nasdaq: CRIS
Curis, Inc. is a drug development company, which is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. The company conducts research programs both internally and through strategic collaborations. It operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.